U.S. SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON D.C. 20549

                                 FORM 12B-25 SEC

                            File Number: 033-55254-28

                            CUSIP Number: 457695 10 4

                           NOTIFICATION OF LATE FILING

                                  (Check One):
            |X| Form 10-K |_| Form 11-K |_| Form 20-F |_| Form 10-QSB

                       For Period Ended: December 31, 2005

Read Attached Instruction Sheet Before Preparing Form. Please Print or Type.
Nothing in this Form shall be construed to imply that the Commission has
verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:

                          PART I-REGISTRANT INFORMATION

                             Full Name of Registrant

                             INNOVATE ONCOLOGY INC.

                          Former Name if Applicable N/a

           Address of Principal Executive Office, (Street and Number)

                 712 Fifth Avenue, 19th Fl, New York, NY, 10019

                        PART II-RULES 12B-25 (B) AND (C)

If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)

|_| a. The reasons described in reasonable detail in Part III of this form could
not be eliminated without unreasonable effort or expense;

|X| b. The subject annual report or semi-annual report/portion thereof will be
filed on or before the fifteenth calendar day following the prescribed due date;
or the subject quarterly report/portion thereof will be filed on or before the
fifth calendar day following the prescribed due date; and

|_| c. The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.

                               PART III-NARRATIVE

The Company accountant needs additional time to complete the complied accounting
information to file a complete and accurate statement.

                            PART IV-OTHER INFORMATION

1. Name and telephone number of person to contact in regard to this notification

Alan Bowen (646) 723 8944

2. Have all other periodic reports required under section 13 or 15(d) of the
Securities Exchange Act of 1934 or section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s). |X| Yes |_| No

3. Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof? |_|
Yes |X| No


If so: attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results can not be made.

Innovate Oncology Inc. (Name of Registrant as specified in charter) has caused
this notification to be signed on its behalf by the undersigned hereunto duly
authorized.

      Date: March 31, 2006

      By___/s/____________________________
      Alan Bowen

      INSTRUCTION: The form may be signed by an executive officer of the
      registrant or by any other duly authorized representative The name and
      title of the person signing the form shall be typed or printed beneath the
      signature. If the statement is signed on behalf of the registrant by an
      authorized representative (other than an executive officer), evidence of
      the representative's authority to sign on behalf of the registrant shall
      be filed with the form.